

AMENDMENTS TO THE CLAIMS

1 - 87. (cancelled)

¹~~88~~. (currently amended) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein comprising the amino acid sequence of SEQ ID NO: 728, wherein the antibody or fragment thereof is conjugated to a diagnostic agent or a cytotoxic agent.

89. (cancelled)

²~~90~~. (previously presented) The antibody or fragment thereof of claim ¹~~88~~, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody.

³~~91~~. (previously presented) The antibody or fragment thereof of claim ¹~~88~~, wherein the fragment is an Fab, F(ab')₂, Fv or sFv fragment.

92-93. (cancelled)

⁴~~94~~. (previously presented) The antibody or fragment thereof of claim ¹~~88~~ ¹~~93~~, wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins.

⁵~~95~~. (previously presented) The antibody or fragment thereof of claim ⁴~~94~~, wherein the radioactive isotope is selected from the group consisting of ²¹¹At, ¹³¹I, ¹²⁵I, ⁹⁰Y, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁵³Sm, ²¹²Bi, ³²P and radioactive isotopes of Lu.

⁶~~96~~. (previously presented) The antibody or fragment thereof of claim ⁴~~94~~, wherein the chemotherapeutic agent is selected from the group consisting of ~~taxol~~, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.

~~7~~⁴97. (previously presented) The antibody or fragment thereof of claim ~~94~~⁴, wherein the toxin is selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.

~~8~~¹98. (previously presented) The antibody or fragment thereof of claim ~~98~~¹, wherein the antibody or fragment thereof further comprises a pharmaceutically acceptable carrier.